• Collagen VI-Enhanced ECM Scaffolds Advance Islet Organoid Ma

  2026-07-14

  This study demonstrates that decellularized amniotic membrane (dAM) hydrogels enriched with collagen VI significantly promote the viability, architectural fidelity, and functional maturation of iPSC-derived islet organoids. These findings offer a robust platform for improving diabetes cell therapy and provide insight into extracellular matrix optimization for organoid engineering.

• Bay 11-7821: Strategic Leverage in Inflammation and Cancer R

  2026-07-14

  This article explores how Bay 11-7821 (BAY 11-7082) revolutionizes inflammatory signaling pathway research and apoptosis regulation studies. By integrating fresh mechanistic insights—such as lactate-driven HMGB1 release in sepsis—with translational strategy, we provide actionable guidance for researchers aiming to push the boundaries of cancer, immunology, and inflammation models. The discussion amplifies beyond standard product profiles, contextualizing APExBIO’s Bay 11-7821 as a tool for next-generation discoveries.

• Workflow Guide: HyperPFU™ High-Fidelity DNA Polymerase (K103

  2026-07-13

  HyperPFU™ high-fidelity DNA polymerase addresses the challenge of amplifying long, difficult, or GC-rich templates where standard PCR enzymes often fail due to low fidelity or limited processivity. It is well-suited for workflows demanding blunt-ended, high-accuracy PCR products, but is not appropriate for protocols requiring 3'-A overhangs or sticky-end generation.

• Calpain Inhibition Restores Offspring Cognition Post-Materna

  2026-07-13

  This study elucidates how excessive calpain activation, triggered by maternal non-obstetric surgery during pregnancy, disrupts BDNF/TrkB-mediated hippocampal development and impairs offspring cognition. Pharmacological inhibition with MDL 28170 partially reverses these effects, highlighting a targeted neuroprotection strategy for perinatal brain injury.

• RP3-340N1.2 Knockdown Destabilizes IL-6 and Limits NSCLC Pro

  2026-07-12

  This study demonstrates that the long non-coding RNA RP3-340N1.2 promotes non-small cell lung cancer (NSCLC) progression by stabilizing IL-6 mRNA. Knockdown of RP3-340N1.2 enhances IL-6 mRNA degradation, suppressing tumor cell proliferation and migration, and provides mechanistic insight for transcriptional regulation research.

• Lymphodepleting Chemotherapy Enhances Neoantigen T Cell Ther

  2026-07-10

  This study uncovers how lymphodepleting chemotherapy, specifically cyclophosphamide and fludarabine, remodels the tumor antigenic landscape to enhance the efficacy of neoantigen-directed adoptive T cell therapy. By increasing immunoproteasome activity and HLA-I expression, chemotherapy synergizes with engineered T cells to improve tumor cell recognition and killing, offering new mechanistic insights for optimizing immunotherapy in solid tumors.

• Cefepime (BMY-28142): Optimizing CNS Infection Research Work

  2026-07-09

  Cefepime (BMY-28142) stands out for its potent blood-brain barrier penetration and broad-spectrum antimicrobial activity, enabling rigorous central nervous system infection models. This article delivers practical protocol enhancements, troubleshooting insights, and evidence-based strategies to advance research on Gram-positive and Gram-negative pathogens.

• Fluorescein TSA Fluorescence System Kit: Unlocking Low-Abund

  2026-07-09

  The Fluorescein TSA Fluorescence System Kit delivers exceptional sensitivity for detecting low-abundance proteins and nucleic acids, transforming IHC, ICC, and ISH workflows. Its robust tyramide signal amplification chemistry, validated in cutting-edge cancer and neuroscience studies, empowers researchers to resolve previously undetectable targets with unmatched clarity.

• I-BET151 (GSK1210151A): Practical Guide for BET Inhibition W

  2026-07-08

  I-BET151 (GSK1210151A) provides selective inhibition of BRD2, BRD3, and BRD4, addressing the need for precise modulation of BET-mediated transcription in cancer biology and epigenetic research. It is best suited for applications such as apoptosis and cell cycle arrest assays in MLL-fusion leukemia or glioblastoma models, but is not recommended for diagnostic or therapeutic use. Researchers should follow strict solubility and storage guidelines to ensure reproducibility.

• PSPro Enables Single-Cell-Type Spatial Proteomics in Tissue

  2026-07-08

  Mao et al. introduce PSPro, a proximity labeling-based method that achieves simultaneous, high-coverage spatial proteome profiling of multiple cell types within intact tissue slices. This innovation overcomes longstanding trade-offs between spatial resolution, throughput, and depth in spatial proteomics, providing new capabilities for analyzing tissue heterogeneity and cell-type-specific protein landscapes.

• Merimepodib (VX-497): Applied Workflows in Antiviral and Imm

  2026-07-07

  Merimepodib (VX-497) is redefining translational research through selective, noncompetitive inhibition of IMPDH, offering robust platforms for antiviral, immunosuppressive, and cancer-related studies. This article delivers actionable protocols, troubleshooting insights, and a synthesis of new virology evidence—enabling researchers to optimize Merimepodib-powered workflows for maximum scientific impact.

• YTHDF1 Phase Separation Drives SSC Fate via IkB-NF-κB-CCND1

  2026-07-07

  This study reveals that liquid-liquid phase separation of YTHDF1, an m6A 'reader' protein, is a pivotal mechanism enabling spermatogonial stem cells to transdifferentiate into neural stem cell-like cells. By demonstrating how YTHDF1 LLPS activates the IkB-NF-κB-CCND1 signaling axis through translational repression of IkBa/b mRNAs, the research offers new insight into cell fate engineering and translational regulation.

• Dual-Action p38α MAPK Inhibitors Accelerate Dephosphorylatio

  2026-07-06

  The reference study uncovers a new dual-action mechanism by which selected p38α MAPK inhibitors not only block kinase activity but also accelerate phosphatase-mediated dephosphorylation of the activation loop. This finding provides structural and mechanistic insight into kinase-phosphatase interplay and informs the design of more potent, specific tools for inflammation and kinase signaling research.

• Bay 11-7821: Precision IKK Inhibition for Inflammation Resea

  2026-07-06

  Bay 11-7821 (BAY 11-7082) empowers researchers to dissect NF-κB-driven inflammation and apoptosis with clarity, offering scalable workflows from in vitro assays to in vivo models. Its unique profile as an IKK inhibitor makes it indispensable for translational studies in cancer, immune modulation, and sepsis.

• Hypoxia Response Modulation Restricts Measles and Nipah Viru

  2026-07-05

  This study demonstrates that pharmacological induction of the hypoxia response pathway—specifically through prolyl-hydroxylase domain (PHD) enzyme inhibition—effectively restricts measles and Nipah virus infections in both in vitro and ex vivo models. These findings highlight host metabolic pathway modulation as a promising antiviral strategy and provide a technical foundation for targeting hypoxia-inducible factor (HIF) signaling in future therapeutic research.

16937 records 1/1130 page Next 12345 下5页 Last page